Pediatric disease burden and vaccination recommendations: understanding local differences  by Gentile, Angela et al.
International Journal of Infectious Diseases 14 (2010) e649–e658Review
Pediatric disease burden and vaccination recommendations: understanding
local differences§
Angela Gentile a,*, Zulﬁqar Bhutta b, Lulu Bravo c, Aly Gamal Samy d, R. Dennis J. Garcia e, Anwar Hoosen f,
Tazul Islam g, Abdollah Karimi h, Mona Salemd, Sriluck Simasathien i, Amir Sohail j,
Veerachai Watanaveeradej k, Karin Wiedenmayer l, Heinz-J. Schmittm
aRicardo Guiterrez Children’s Hospital, Gallo 1330 (1425) Buenos Aires, Argentina
bAga Khan University, Karachi, Pakistan
cUniversity of the Philippines, Manila, Philippines
dAin Shams University, Cairo, Egypt
eMakati Medical Center, Makati, Philippines
fUniversity of Pretoria, South Africa
g EPI Mohakhali, Dhaka, Bangladesh
hResearch Center of Pediatric Infectious Diseases, Beheshti University, Moﬁd Hospital, Tehran, Iran
i Pediatric Infectious Diseases Society of Thailand, Bangkok, Thailand
j 22/20 B Khiljee Road, Block-B, Mohammadpur, Dhaka-1207, Bangladesh
k Phramongkutklao Hospital, Bangkok, Thailand
l Swiss Tropical Institute, Basel, Switzerland
mNovartis Vaccines and Diagnostics GmbH & Co. KG, Marburg, Germany
A R T I C L E I N F O
Article history:
Received 16 April 2009
Received in revised form 26 August 2009
Accepted 5 November 2009
Corresponding Editor: William Cameron,
Ottawa, Canada
Keywords:
Pertussis
Diphtheria
Tetanus
Hepatitis B
Haemophilus inﬂuenzae type b
Measles
A B S T R A C T
Background: Diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HepB), invasive Haemophilus inﬂuenzae
type b (Hib) disease, and measles cause substantial global morbidity and mortality.
Methods: This unique review highlights geographic differences in disease burden across certain
countries in the African, Americas, Mediterranean, South-East Asian, and Western Paciﬁc World Health
Organization (WHO) regions, and relates this to vaccination coverage and local vaccine recommendations
using the authors’ countries as illustrations.
Results: Substantial differences were observed in the incidence of these diseases and in vaccination
coverage between the countries studied.Disease incidenceoften reﬂected inadequate surveillance, but also
variable or poor vaccination coverage. Vaccination coverage against HepB was particularly low in the
African and South-East Asian WHO regions; vaccination coverage against invasive Hib disease was low in
these regions and in the Eastern Mediterranean and Western Paciﬁc WHO regions. Vaccination schedules
within some countries in these regions do not include, or have only recently included, vaccinations against
HepB and Hib disease. The use of DTwP–HepB–Hib (diphtheria, tetanus, whole-cell pertussis, HepB, Hib)
combination vaccines has now been adopted by some countries to help increase vaccination coverage.
Conclusions: Vaccination coverage and vaccination schedules vary markedly between the countries
studied, often according to the resources available. DTwP–HepB–Hib combination vaccines represent a
cost-effective option, with the potential to substantially reduce the burden associated with these
diseases by increasing coverage and compliance.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j id§ The information given here was presented at the Quinvaxem Advisory Board
meeting at the 13th International Congress on Infectious Diseases, Kuala Lumpur,
Malaysia, June 19, 2008.
* Corresponding author. Tel./fax: +54 11 4964 9019.
E-mail address: angelagentile@ﬁbertel.com.ar (A. Gentile).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.11.0061. Introduction
Diphtheria, tetanus, pertussis, hepatitis B (HepB), invasive
Haemophilus inﬂuenzae type b (Hib) disease, and measles are all
serious childhood diseases that are associated with signiﬁcant
levels of morbidity and mortality. The reported incidence of these
diseases varies across countries and regions, as does the proportion
of cases reported to result in death (Table 1).1–14 It is believed that
there is a large amount of under-reporting of these diseases, partlyses. Published by Elsevier Ltd. All rights reserved.
Table 1
Global reported incidence, estimated actual global incidence and prevalence, and mortality of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus inﬂuenzae type b (Hib)
disease, and measles1–14
Disease Global reported
incidence (cases/year)
Estimated actual global
incidence/prevalence
Mortality Data sources
Diphtheria 7088 Unknown 5–10% (20% in
those <5 years of age)
CDC 20081
WHO 20102
Tetanus 16 628 Incidence: 1 million 11% Bleck 20053
CDC 20084
WHO 20105
Pertussis 152 535 Incidence: 17.6 million 1.6% WHO 20056
WHO 20087
Hepatitis B 914 000 Prevalence: 350–360 million 600 000/yeara WHO 20048
WHO 20089
WHO 200810
Hib disease 3 million Unknown 386 000/year WHO 200511
WHO 200612
Measles 281 972 Unknown 1–5% (developed countries);
up to 25% in certain countries
WHO 200913
WHO 200814
Data relate to 2007 or latest available data, unless otherwise stated. CDC, Centers for Disease Control and Prevention; WHO, World Health Organization.
a Includes chronic consequences of hepatitis B.
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developing countries. There is also a lack of surveillance, or weak
surveillance programs. For example, although the documented
global annual incidence of tetanus was 16 628 cases in 2008,5 the
actual incidence is believed to be closer to 1million cases per year.3
This is also the case with pertussis, for which the reported annual
incidence is 151 586,7 whereas it has been estimated that
approximately 17.6 million cases occur each year.6 Difﬁculty in
detection may also affect disease reporting. Although millions
of people are known to develop invasive Hib disease every year
(2 200 000 estimated cases with 325 000–500 000 deaths per year
worldwide),15 it is difﬁcult to diagnose as it causes a range of
illnesses, sometimes with non-speciﬁc symptoms, and conﬁrma-
tion by laboratory testing may be expensive and can be
challenging, requiring special agar and sera, and staff trained in
and equipped for diagnosis. It is likely, therefore, that the
estimated incidence of invasive Hib disease and the numbers of
cases and mortalities are underestimates, and many of those
infected die without the disease being diagnosed or reported.
Together, these vaccine-preventable diseases cause a substan-
tial disease burden affecting populations worldwide, particularly
in developing countries. Once any of these diseases is contracted,
treatment options can be extremely limited, particularly for
measles, pertussis, and HepB, with most treatments focused on
providing symptomatic relief. Therefore, the most effective
strategy to combat these diseases is disease prevention, particu-
larly through vaccination. Vaccination has been shown to be one of
the most effective public health interventions worldwide,16
through which a number of serious childhood diseases have been
successfully eradicated. For example, as a result of vaccination,
polio has now been eradicated from the Americas (in 1994), the
Western Paciﬁc (in 2000), and the European World Health
Organization (WHO) regions (in 2002).17
TheWHO recommends vaccination against a number of serious
infectious diseases, including diphtheria,18 tetanus,19 pertussis,6
HepB,8 invasive Hib disease,12 and measles20 for all children, and
against pneumococcal disease, yellow fever, and rotavirus disease
for children in some areas as part of their Expanded Program on
Immunization (EPI). However, many infants and children still die
every year from diseases that could be prevented by implementing
the WHO vaccination recommendations.21 It has been shown that
approximately 27 million infants are not vaccinated against
common childhood diseases, such as measles or tetanus. As a
result, 2–3 million children will die annually from easily
preventable diseases, and many more will fall ill.22Developing countries can ﬁnd the implementation of vaccina-
tion programs challenging and may not have the ﬁnancial
resources available to incorporate new vaccines into their
schedules. The availability of cost-effective combination vaccines
could make the implementation of complex schedules more
achievable, through a number of economic and logistical beneﬁts,
including time gains in administration and throughout the supply
chain,23 aswell as through enhancing timeliness and compliance in
schedule completion.24 Vaccination has the additional beneﬁt of
decreasing the inequity brought about by inaccessibility ofmedical
care to the poor. For the local communities, providing vaccination
brings beneﬁts in terms of reducedmorbidity, greater productivity,
and improved economic savings and gains.25
The aim of this review is to provide an insight into disease
burden, vaccination recommendations, and vaccination coverage
across a range of geographical regions. The review is based on
discussions from an experts’ meeting of pediatricians from several
different countries and regions. The broad geographical and
socioeconomic spread of the countries that are represented allows
a balanced analysis of the current situation; this may be particular
to the country of origin of the meeting attendees rather than to the
WHO region.
It is our hope that this unique review will help to facilitate
implementation of vaccination support that is tailored to local
needs, and will play a part in increasing vaccination coverage by
promoting greater awareness of current challenges. Such improve-
ments in vaccination coverage are essential to control disease
outbreaks, and reduce themorbidity andmortality associatedwith
vaccine-preventable childhood diseases.
2. Regional variation in disease burden
While global statistics provide a useful overview of disease
burden, examination of regional variations across the countries
studied reveals clear differences in geographical distributions for
diphtheria, tetanus, pertussis, HepB, and measles (Figure 1).8,26–33
The vast majority of diphtheria cases occur in the South-East Asian
WHO region; this region also has the greatest proportion of
tetanus, pertussis, and HepB cases. The greatest proportion of
measles cases are found in the Western Paciﬁc WHO region.
The distribution of cases appears much clearer when countries
are classiﬁed as developed or developing, with the vast majority of
cases of diphtheria (99.0%), tetanus (99.2%), pertussis (71.5%), and
measles (98.8%) occurring in developing countries.34 Indeed, more
than 95% of measles cases occur in countries that have both a per
Figure 1. Distribution of cases of diphtheria, tetanus, pertussis, and measles (2007 data), and for hepatitis B (HepB) (2002 data) by World Health Organization region.8,26–33
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inefﬁcient healthcare system.13 The situation is similar for HepB;
approximately three-quarters of the HepB cases in 2002 occurred
in the African, South-East Asian, and Western Paciﬁc WHO
regions.8
There is also a notable geographical split with regard to the
burden of disease. Invasive Hib disease remains one of the most
signiﬁcant challenges in developing countries, where Hib pneu-
monia is more common than Hib meningitis.11 The challenge of
making a deﬁnitive diagnosis, particularly in developing countries,
results in a signiﬁcant underestimation of the impact of Hib
disease. In particular, it can be difﬁcult to make a diagnosis of Hib
pneumonia in children, as low levels of bacteremia lead to the
majority of blood samples appearing negative. In Latin American
countries, before Hib vaccination was more widely introduced, the
most common diagnosis was of meningitis. More recently, the
WHO evaluated the evidence from probe trials and other high-
quality estimates, and recommended that the burden of invasive
Hib disease is sufﬁcient to warrant introduction of Hib vaccine for
all children, and that a lack of local data should not be a reason to
delay the introduction of the vaccine.12 This approach also applies
to other vaccines, such as those for the prevention of invasive
pneumococcal disease.35
These data illustrate how regional and socioeconomic factors
affect the incidence and mortality rates of these common vaccine-
preventable childhood diseases. Both the quality of reporting, in
terms of the completeness of information and laboratory
conﬁrmation, and its quantity, as many regions have inadequate
surveillance, are currently limited. In order to more fully
understand the degree of regional variation, we sought to bring
together representatives from key countries to derive a best
estimate of disease burden by country.
3. Disease burden by country and region
The incidence of diphtheria, tetanus, pertussis, HepB, Hib
disease, and measles for the authors’ and contributors’ countries isshown in Table 2.33,36–44 This direct comparison reveals large
variations in reported disease incidence, not only between
different WHO regions (e.g., for HepB in the Americas region
compared with the South-East Asian region), but also between the
countrieswithin eachWHO region (e.g., formeasles between Egypt
and Iran).
Of particular note, invasive Hib disease appears to be
uncommon in Egypt, and the vaccine is still not included in the
national immunization programme.45 Pakistan has one of the
highest reported incidences of this disease in the region, with an
annual incidence of approximately 1 in every 100 children.
Similarly, there is a relatively low incidence of HepB in Thailand,
while Bangladesh, in the same region, has one of the highest HepB
incidences of the countries studied here (Table 2).33,38,39,41–43
Conversely, among the highest burdens of HepB can be found in
South-East Asia and the Philippines, where the incidence is as high
as 10–12% of the population.46 The reduced incidence seen in
Thailand was brought about by the introduction of a ﬁrst dose of
HepB vaccine at birth. This birth dose was also introduced in the
Philippines in 2007; however, only administration of the second
and third doses (at 6 and 14 weeks) will ensure adequate
protection from disease in the longer term.
While some countries have succeeded in reducing the incidence
and subsequent burden of individual diseases, no country in this
study has successfully achieved good control of all the targeted
diseases – diphtheria, tetanus, pertussis, HepB, Hib disease, and
measles. In Argentina, for example, which is free from reported
diphtheria, childhood HepB, and measles, pertussis remains a
signiﬁcant burden, with a mortality rate of 3.5% in pertussis
patients <12 months of age (A. Gentile, personal communication,
2008). The high incidence of Hib disease in Pakistan results in an
estimated 25 000 disease-associated deaths per year,47 neonatal
tetanus has amortality rate of up to 11.6 per 1000 live births,48 and
approximately 2% of the population is reported to be positive for
HepB.38
Many factors, including population density and hygiene
standards, have a signiﬁcant inﬂuence on disease incidence.
Table 2
Incidence per 100 000 individuals of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus inﬂuenzae type b disease, and measles in countries within different World Health Organization regions29
WHO region and country Diphtheria Tetanus Pertussis HepBa Hiba Measles Data source(s)
African
South Africa 0 (5 cases in 2007;
1 case in 2008)
0 (21 cases in 2007) 0 (3 cases in 2007) 1 (485 cases in 2007) 0.04 (24 cases
in 2007)
0.2 (114
cases in 2007)
Republic of South Africa
Department of
National Health 200536
Americas
Argentina 0 0–0.2 (neonatal tetanus:
0 cases; all tetanus:
6 cases)
3.8–6.5 0 0.05 0 WHO 200833
Boletı´n Epidemiolo´gico
Anual 200637
Eastern Mediterranean
Egypt 0 0.05 0 . . . . . . 2.2 WHO 200833
Iran 0.045 0.015 0.37 . . . . . . 0.19 WHO 200833
Pakistan 0.01 0.45 0.16 1.7–5.5% positive
for HepB
893 (children
0–4years of age)
1.7 WHO 200833 Ali et al. 200938
Nizami et al. 200639
Saudi Arabia 0.01 0.03–0.11 0.14–0.27 18.2 1.08 3.41–18.8 Ministry of Health,
Saudi Arabia 200640
WHO 200833
South-East Asian
Bangladesh 0.05 0.14–0.65 0.05 6700 (currently
9–13 million
of population infected)
No clear consensus 1.84
WHO 200829 Liver Foundation
of Bangladesh 200641
Sri Lanka 0 0.23 0 . . . . . . 0.23 WHO 200833
Thailand <0.01 0.21 0.04 6.9 3.8 in children under
5 years of age for
meningitis only
6.1–6.2 Rerks-Ngarm et al. 200442
Bureau of Epidemiology,
Thailand 200743 WHO 200833
Western Paciﬁc
Philippines 0.04–0.05 0.02 0.02 (0.6 among
children)
6.8 among children 94.6 (children
under 5 years of age)
0.6 Limcangco et al. 200044
[Ref. 44?] WHO 200833
Data relate to 2007 or latest available data, unless otherwise stated. HepB, hepatitis B; Hib, Haemophilus inﬂuenzae type b; WHO, World Health Organization.
a Ellipses indicate no data available.
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illnesses affect the morbidity and mortality rates associated with
these diseases. In addition, vaccination coverage may have a
signiﬁcant impact. The ﬁndings presented here are also dependent
on appropriateness of surveillance and reporting, which is known
to be poor in some areas.
4. Regional variations in vaccination coverage and
recommendations
Vaccines for inclusion in national programs are recommended
by the WHO Expanded Program on Immunization (EPI). However,
these recommendations are not universally adopted, which may
lead to discrepancies in vaccination coverage between and within
countries.
4.1. Vaccination coverage
In theWHOAfrican and South-East Asian regions, low uptake of
DTP3 vaccination (the third dose of diphtheria, tetanus, and
pertussis combination vaccine, to complete the primary vaccina-
tion course) among infants (those <1 year of age) results in an
estimated vaccination coverage of <75% (Figure 2),2,34 which is
well below the WHO target of 90%.49 Vaccination coverage for the
third dose of HepB and measles-containing vaccine (MCV1) are
also low in Africa and South-East Asia (Figure 2).2,14,34 In the
Eastern Mediterranean, South-East Asian, and Western Paciﬁc
WHO regions, the estimated vaccination coverage for Hib in infants
is very low (0–16%). Vaccination coverage for HepB among infants
is also low in the African and South-East Asian WHO regions
(Figure 2).2,34 The low vaccination coverage against HepB and Hib
disease in these regions, therefore, represents a signiﬁcant
healthcare gap, especially given the high burden of HepB in
countries such as Bangladesh, and of invasive Hib disease in
countries such as Iran and Pakistan33,38,39,41 (Table 2).
Although DTP coverage is generally good in the Philippines,
protection of infants against neonatal tetanus through vaccination
of pregnant mothers has been relatively low, with poor vaccine
uptake following politically inspired claims that the tetanus toxoid
component would induce miscarriage, despite adequate and
reliable data to the contrary.50 Coverage is now improving, and
2006 data suggest that 64% of infants were protected.51
Even where national vaccination coverage is above the WHO
target, the local situation can vary considerably. For example, inFigure 2. Estimated vaccination coverage among infants <1 year of age, for the third dos
and Haemophilus inﬂuenzae type b (Hib3), and for the ﬁrst dose of measles-containing vac
WHO targets, where applicable.2008 in the Western Cape region of South Africa, coverage for a
range of childhood vaccinations was reported as 53.2% by 18
months of age,52 whereas far higher vaccination coverage was
observed on a national level. Poor vaccination coverage, whether
locally or across a WHO region, has been proven to lead to
outbreaks of disease and epidemics; this was observed in
Argentina, where an outbreak of pertussis resulted in an increase
in reported cases from 976 in 2004, to 2060 in 2005, and 1607 in
2006.34 Measles outbreaks have also been reported in speciﬁc
communities where vaccine uptake was low in Germany, northern
Italy/Austria, Switzerland (Tyrol), and the USA,53–56 as well as in
the UK following a period of parental concern over the safety of the
measles, mumps, and rubella (MMR) vaccine.33,57
4.2. Vaccination recommendations
Examination of the variation in vaccination recommendations
between countries and regions provides an insight into the
priorities of vaccination programs, and how the implementation of
vaccination programs may be improved.
Recommended vaccination schedules for individual countries
(Table 3)33 highlight substantial variations between countries and
regions in the timing and number of doses of the vaccines that are
recommended.58 For example, in some countries, only three doses
of DTP are recommended, whereas others recommend that ﬁve or
six doses be administered, including toddler, pre-school, and
adolescent boosters. Also, for HepB vaccination, some countries
recommend administering doses according to the EPI recommen-
dation of 6–10–14 weeks, whereas others recommend that this
vaccine be given at 2–4–6 months, with or without a dose at birth.
In many cases, however, details of vaccination goals are not
available and so meaningful comparisons are difﬁcult. Moreover,
details of how vaccination goals are implemented or achieved are
either not publicly known or do not exist for some countries.
It is notable that for some countries, the incidence of certain
diseases (Table 2) is higher than would be expected from the
vaccination schedules shown in Table 3.33 This may be partly due
to low vaccination coverage (Table 4)33 and to the vaccination
recommendations within these countries. For example, in the
Philippines, the birth dose of HepB vaccine was not included in the
recommended vaccination schedule until 2007, which may partly
account for the high childhood incidence of HepB. A measles
elimination programwas started by the Philippines Department of
Health in 2004, vaccinating all children 9 months to 8 years of age,e of vaccines against diphtheria, tetanus, and pertussis (DTP3), hepatitis B (HepB3),
cine (MCV1), byWorld Health Organization (WHO) region.2,34 Dotted lines indicate
Table 3
Recommended vaccination schedules for diphtheria, tetanus, and pertussis, hepatitis B, Haemophilus inﬂuenzae type b disease, and measles in countries within different
World Health Organization regions29
WHO region and country DTP HepB Hiba Measles
African
South Africa 6, 10, 14 weeks; 18 months 6, 10, 14 weeks 6, 10, 14 weeks; 18 monthsb 9, 18 months
Americas
Argentina 2, 4, 6, 18 months; 6 years Birth; 2, 6 monthsc 2, 4, 6, 18 monthsb 1, 6 years
Eastern Mediterranean
Egypt 2, 4, 6, 18 months 2, 4, 6 months ... 12 months (as MMR)
Iran 2, 4, 6, 18 months; 4–6 years Birth; 2, 6 months ... 12 months; 4–6 years
Pakistan 6, 10, 14 weeks 6, 10, 14 weeksb 6, 10, 14 weeks (2008 onwards)c 9 months
Saudi Arabia 2, 4, 6 months (as DTP–HepB–Hib);
18 months (as DTP–Hib); 4–6 years
Birth; and 2, 4, 6 months
(as DTP–HepB–Hib)
2, 4, 6 months (as DTP–HepB–Hib);
18 months (as DTP–Hib)
9 months (2008 onwards);
1, 4–6 years
South-East Asian
Bangladesh 6, 10, 14 weeks 6, 10, 14 weeks ... 38 weeks
Sri Lanka 2, 4, 6, 18 months; 5 yearsd 2, 4, 6 months 2, 4, 6 months (2008 onwards)c 9 months; 3 years
Thailand 2, 4, 6 months; 1.5–2, 4–6 years Birth; 2, 6 months; or birth
(HepB only); 2, 4, 6 months
(as DTP–HepB)
... 9–12 months; 4–6 years
Western Paciﬁc
Philippines 6, 10, 14 weeks Birth; 6, 14 weeks ... 9, 18 months
Data relate to 2007 or latest available data, unless otherwise stated.WHO,World Health Organization; DTP, diphtheria, tetanus, pertussis; HepB, hepatitis B; Hib,Haemophilus
inﬂuenzae type b; MMR, measles, mumps, and rubella vaccine.
a Ellipses indicate no data available.
b Included as a multi-component vaccine with DTP.
c Included as part of DTP–HepB–Hib vaccination from 2008.
d Vaccination at 5 years of age only includes DT.
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ty andmortality. The target of eliminatingmeasles by 2010 is likely
to be achieved in the Philippines. Although measles is included in
the recommended vaccination schedules of most countries,
vaccinations against mumps and rubella (individually or as part
of the measles and rubella (MR) or MMR combination vaccine) are
not recommended in Bangladesh, Pakistan, the Philippines, or
South Africa, and in Sri Lanka, there is no recommendation for
vaccination against mumps. In the Philippines, although rubella
vaccination is included in the EPI, this has not yet been
implemented.
For various reasons, including lack of local evidence, lack of
awareness, or lack of resources, many countries still do not include
Hib vaccination in their recommended vaccination schedules. This
is despite the relatively high burden of disease in some of these
countries, e.g., Iran. However, the inclusion of Hib vaccination fromTable 4
Ofﬁcial 2007 country estimates of vaccination coverage (%) by antigen for diphtheria, tet
containing vaccine for countries within different World Health Organization regions29
WHO region and country DTP1a DTP3b HepB1c
African
South Africa 99 97 ...
Americas
Argentina 94 96 79
Eastern Mediterranean
Egypt 98 98 ...
Iran 99 99 99
Pakistan 90 83 ...
Saudi Arabia 97 96 96
South-East Asian
Bangladesh 98 87 ...
Sri Lanka 99 98 ...
Thailand 99 98 99
Western Paciﬁc
Philippines 90 87 9
WHO, World Health Organization; DTP, diphtheria, tetanus, pertussis; HepB, hepatitis
a First dose of DTP vaccine.
b Third dose of DTP vaccine.
c First (birth) dose of HepB vaccine.
d Ellipses indicate no data available.
e Third dose of HepB vaccine.
f Third dose of Hib vaccine.2008 onwards as part of a DTP–HepB–Hib vaccine in Pakistan and
Sri Lanka should help to reduce the high burden of this disease in
these countries. The adoption of Hib vaccine is accelerating in the
poorest countries, with the vast majority planning to introduce the
vaccine with support from the Global Alliance for Vaccines and
Immunisation (GAVI) in 2009 and 2010. Many lower-middle
income countries still have not made the decision to adopt the
vaccine, mainly due to cost concerns. Following the development
of the Child Survival Strategy to meet Millennium Development
Goal 4 of reducing infant and childhoodmortality, plans have been
announced to include vaccination against Hib disease in the
Philippines, although the date of introduction is unknown. In
addition to the promotion of good nutrition, and a clean and safe
water supply, the introduction of new and underutilized vaccines,
particularly against pneumonia (including Hib), is one of the major
interventions for child survival.59anus, and pertussis, hepatitis B, Haemophilus inﬂuenzae type b disease, and measles-
,d HepB3e Hib3d,f MCV MCV2d
97 97 83 69
92 96 99 91
98 ... 97 97
97 ... 97 97
83 ... 80 ...
96 96 96 ...
87 ... 85 ...
98 ... 98 97
96 ... 96 94
88 ... 92 ...
B; Hib, Haemophilus inﬂuenzae type b; MCV, measles-containing vaccine.
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vaccination recommendations are made by a national committee
of governmental advisers or by the ministry of health. In most
cases, vaccination is then funded by the government, although this
can be facilitated by local government in some countries (e.g., the
Philippines). In Sri Lanka, vaccinations are partly funded by the
government, in conjunction with the EPI and GAVI Alliance. The
GAVI Alliance provides support for vaccine ﬁnancing to 72
countries with low gross national product, including Pakistan, as
does the United Nations Children’s Fund (UNICEF) in Bangladesh.
Althoughmany countries provide funding for vaccination, there
are several factors thatmay prevent vaccination coverage reaching
targets. For example, in South Africa, the falling number of nurses
restricts the implementation of vaccination recommendations.
This has led to a growing private market in South Africa and in
other countries such as Bangladesh. In the Philippines, vaccines not
included in the EPI recommendations must be paid for by the
patient, which is likely to have a detrimental effect on vaccine
uptake. About 10–15% of recommended childhood vaccinations,
including Hib vaccine, are provided through private clinics,
together with other non-EPI vaccines (L. Bravo, personal commu-
nication, 2008).
4.3. Summary
All of the authors’ countries recommend vaccination against
diphtheria, tetanus, pertussis, and measles. Although vaccination
against HepB is recommended in all of the authors’ countries, this
has only recently been implemented in many countries, and the
absence of a birth dose is reﬂected in high incidence rates of HepB
among children in some countries. Vaccination against invasive
Hib disease is still not recommended in all countries, and requires
private funding in some countries; however, it has recently been
introduced to some countries with a high Hib disease burden. It
should also be noted that pneumococcal conjugate vaccine is being
introduced as part of GAVI Alliance initiatives to prevent
pneumococcal infection.
The introduction of pentavalent vaccines, currently used in
Saudi Arabia, and recently introduced in Argentina, Pakistan, and
Sri Lanka, allows cost-effective vaccination against HepB and Hib
disease as an add-on to the existing DTP vaccination. The use of
whole-cell pertussis (wP) vaccines (i.e., DTwP–HepB–Hib) makes
the vaccines more affordable than their acellular pertussis (aP)
counterparts, and the suitability of these vaccines in the
implementation of EPI vaccination programs contributes to a
reduction in Hib disease in countries such as Argentina, where they
have been introduced.
5. Discussion
Vaccination programs have successfully reduced disease
burden in developing countries. In the Gambia, for example, the
incidence of invasive Hib disease per 100 000 children <5 years of
age decreased from approximately 60 cases in 1990–1993 to 0
cases in 2002 following the introduction of Hib vaccination.60More
recently, similar success has been seen in Uganda following
vaccine introduction, where Hib meningitis incidence dropped
from 88 cases per 100 000 children <5 years of age in the year
before vaccine introduction to 13 cases within 4 years, and to
almost zero in the ﬁfth year. In Uganda, it is now estimated that Hib
vaccine prevents some 28 000 cases of Hib pneumonia and Hib
meningitis, 5000 deaths, and 1000 severe Hib-meningitis sequelae
each year.61 However, the issue remains that surveillance is still
poor in many countries, and vaccination coverage for some key
pediatric vaccines is lower in some countries than recommended
by the WHO. Substantial differences have also been reportedbetween ofﬁcial and survey-based measures of vaccine coverage,
indicating that coverage may not be as great as reported ﬁgures
suggest.62 Moreover, in many countries within the Eastern
Mediterranean and South-East Asian WHO regions, recommended
vaccines have not been incorporated into national programs. The
information brought together here shows that a clear correlation
exists between the adoption of a given vaccine into the national
schedule, vaccine coverage, and disease incidence, reinforcing the
case for widespread pediatric vaccination to reduce the burden of
disease.
Despite vaccination recommendations, the pediatric disease
burden remains high in many regions. Hepatitis B and Hib disease
contribute substantially to this disease burden in the Eastern
Mediterranean and South-East Asian WHO regions. Unfortunately,
many of the regionswith the highest disease burden are associated
with very low levels of diagnosis and disease surveillance. This
problem is more common in the Eastern Mediterranean, South-
East Asian, andWestern PaciﬁcWHO regions, where there is a need
for improved surveillance, to capture data accurately and assess
the magnitude of the disease burden. Here, sentinel surveillance
carried out on a widespread basis by local organizations could
provide invaluable information about disease incidence, which
would help to establish the true burden of disease in many
developing countries. Surveillance needs to be of a high quality,
however, to help avoid the potential for decision-making based on
incomplete or potentially misleading results. Models, such as
recent global disease burden models for Hib, pneumococcus, and
measles, may be required to establish a truer picture of disease
burden. Suchmodels provide country-level estimates and take into
account probe studies or other regional information where local
data are insufﬁcient.
There is also a large degree of variation between countries in
terms of vaccination recommendations. These variations are often
driven by lack of resources, and can lead to confusion regarding
regional vaccination priorities. In addition, with increasing
numbers of diseases for which vaccinations are recommended,
vaccination programs become complex and can be challenging to
implement, leading to sub-optimal vaccination coverage.
The incorporation of new vaccines into already complex
schedules can prove challenging to healthcare providers, particu-
larly in areas of developing countries and in regions with isolated
populations. An increased number of injections, both in total and
per visit, can lead to distressed patients and parents, which may
deter parents from attending clinic visits, and therefore may act to
reduce compliance with vaccination schedules.63,64 An example of
the number of vaccinations that may be required can be drawn
from the USA, where the vaccination schedule for children
2 years of age increased from ﬁve injections and four sets of
oral drops in 1983, to 20 injections in 2003.65 Parents often express
concern about the number of injections per visit received by their
children.63 However, scheduling additional vaccination visits to
reduce the number of injections per visit increases time and costs,
burdens healthcare staff, and may risk the success of a vaccination
program by increasing the likelihood of missed visits.64
The use of combination rather than separately administered
vaccinesmay facilitate the implementation of complex vaccination
programs. Combination vaccines have been proven to offer
comparable or even superior immunogenicity to separate admin-
istration of individual components,66 and have also been shown to
lead to higher compliance rates, and therefore more complete
vaccination coverage, since fewer clinic visits and injections are
required.24,67–69 A time andmotion study carried out in India using
a fully liquid combination vaccine also identiﬁed signiﬁcant
savings throughout the whole supply chain, as well as time
savings at the facility level compared with lyophilized vaccines
requiring reconstitution. This translated into economic savings
A. Gentile et al. / International Journal of Infectious Diseases 14 (2010) e649–e658e656which could be key in countries with limited economic
resources.23
Additionally, combination vaccines that include the wP
component offer additional cost savings over those that include
the aP component.6 A number of studies have compared wP- with
aP-containing vaccines, and found some wP vaccines may provide
greater protection than some aP vaccines,70 and that the wP
component does not adversely affect the immune response to
Hib.71 Moreover, recent data from Rieber and colleagues suggest
that wP vaccines may produce more effective priming of B cell
memory and, therefore, offer better long-term protection – amajor
goal in the future improvement of pertussis vaccines.72 Whole-cell
pertussis vaccines can be more reactogenic than aP vaccines;
recent comparative studies have shown that although local
adverse reactions are less frequent with the aP-containing vaccine
compared with wP, there is no signiﬁcant difference in systemic
reactions except for fever, and that wP combination vaccines have
an acceptable safety and tolerability proﬁle.73 By virtue of the
combination of efﬁcacy, tolerability, and cost-effectiveness, the
WHO recommends that wP combination vaccines should be the
vaccines of choice in regions where resources may be limited.6
These factors will be key in expanding vaccine coverage into the
developing countries highlighted here, where there remains a
signiﬁcant unmet need.
By the end of 2008, it was estimated that over 50 million
children had been vaccinated with DTwP-based pentavalent
vaccine, with 49 countries now eligible for GAVI Alliance
support.74 This is a signiﬁcant increase over ﬁgures reported for
2007, at which time 28 million children had received pentavalent
vaccine across 39 countries.75 Focused efforts to inform countries
of the burden of disease, beneﬁts of vaccination, and availability of
vaccine and ﬁnancial support have helped to drive the increase in
vaccine uptake. The availability of the vaccine in a fully liquid
formulation has also been a signiﬁcant factor in increasing
uptake.74 Of 29 countries that applied to the GAVI Alliance for
help in strengthening their vaccination systems in 2007, 20
requested support in obtaining pentavalent vaccines. Of these, 16
(80%) expressed a preference for a fully liquid vaccine, indicating
that it is the favored option, particularly in countries of limited
means.76
This review has highlighted considerable geographical variance
in the burden of childhood disease and vaccination coverage in the
countries studied. Combination vaccines that are cost-effective
have the potential to increase vaccination coverage against
common childhood diseases, and reduce their substantial disease
burden. Theymay also enhance the implementation of vaccination
programs and release budget for the incorporation of additional
vaccines into existing programs, further extending vaccination
coverage and reducing the substantial morbidity and mortality
associated with vaccine-preventable diseases.
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